Extracorporeal Membrane Oxygenation, Pharmacokinetics
Conditions
Keywords
Extracorporeal Membrance Oxygenation, Pharmacokinetic medeling, Antiplatelet agents, Sedatives, Antibiotics
Brief summary
The purpose of this study is to optimize the dosage regimen of drugs in patients during during Extracorporeal Membrane Oxygenation (ECMO) by population pharmacokinetic modeling.
Interventions
OTHERResidual blood
Residual blood samples(1\ 2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
Sponsors
Yonsei University
Gachon University Gil Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who are taking levofloxacin, meropenem, vancomycin, cefepime, midalzolam, dexmedetomidine, propofol, clopidogrel, ticagrelor, or prasugrel while underdoing Extracorporeal Membrane Oxygenation
Exclusion criteria
* Pregnant women * Receiving a therapy that can affect blood concentration due to a drug-drug interaction with levofloxacin, meropenem, vancomycin, cefepime, midalzolam, dexmedetomidine, propofol, clopidogrel, ticagrelor, or prasugrel
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic parameters | Day 0 to day 3 during ECMO, Day 0 to day 3 after removing ECMO | Volume of distribution |
Countries
South Korea
Contacts
Primary ContactJin Wi, Prof
Outcome results
None listed